Now biomaterials of the drug are studied at the National Center for Expertise of Medicines and Medical Devices.
On October 28, President of Kazakhstan Kassym-Zhomart Tokayev received the head of the Research Institute for Biological Safety Problems Kunsulu Zakarya. Political and scientific figures discussed the dynamics of the development of a domestic vaccine against coronavirus. It was reported to CentralAsia.news by the press office of Akorda.
As part of the report on the current situation, the specialist told about the effective work on the vaccine, which is developed at five research blocks of the institute. The scientist said that the inactivated vaccine, previously created at the research institute and approved by the WHO, has completely passed clinical trials. At the moment the second stage of testing of the drug is conducted at the Research Center for Phthisiopulmonology.
The biologist noted that the second subunit vaccine has also been studied within clinical conditions and was approved by the WHO. Now its biocomponent composition has been sent to the National Center for Expertise of Medicines and Medical Devices for certification.
The head of the state considered the information on the construction of a plant for the production of immune drugs based on the research institute a significant step in the development of domestic immunobiology. The design capacity of the enterprise will be 60 million doses per year, which will cover internal needs and supply for export.
The president and the head of a large research institute also discussed social issues. They touched upon the expansion of living space for research workers, an increase in wages and work conditions for young specialists.